William Blair Reaffirms Outperform Rating for Bionomics (NASDAQ:BNOX)

William Blair reiterated their outperform rating on shares of Bionomics (NASDAQ:BNOX) in a research note released on Friday morning,RTT News reports.

Separately, HC Wainwright reiterated a “buy” rating and set a $8.00 price objective on shares of Bionomics in a research note on Thursday, August 1st.

Bionomics Stock Performance

Shares of BNOX traded down $0.03 during midday trading on Friday, hitting $0.29. 419,169 shares of the stock traded hands, compared to its average volume of 3,067,924. Bionomics has a 1-year low of $0.18 and a 1-year high of $2.19. The business’s 50 day moving average price is $0.40 and its two-hundred day moving average price is $0.64.

Institutional Investors Weigh In On Bionomics

An institutional investor recently bought a new position in Bionomics stock. Armistice Capital LLC acquired a new position in Bionomics Limited (NASDAQ:BNOX) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 1,226,759 shares of the company’s stock, valued at approximately $941,000. Armistice Capital LLC owned approximately 15.03% of Bionomics at the end of the most recent quarter. Institutional investors and hedge funds own 15.90% of the company’s stock.

About Bionomics

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.